Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma
US6500919B1 · kind B1 · utility
77Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 15, 1995 |
| Grant date | Dec 31, 2002 |
| Priority date | — |
| Expiry date | Feb 15, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/822
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A melanoma associated antigen known as gp100. Furthermore, peptides derived from the antigen are described. Gp100 and its peptides can be used in vaccines for the treatment of melanoma. Another aspect of the invention is host cells capable of expressing gp100 for the gp100-derived peptides. Furthermore, tumor infiltrating lymphocytes (TIL's) specifically recognizing gp100 are described, as are vaccines with these TIL's. Also disclosed are diagnostics for the detection of melanoma and for the monitoring of vaccination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.